(Q51768350)

English

Phase II trial of Belagenpumatucel-L, a TGF-beta2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients.

scientific article published on 13 March 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

11 April 2018

http://europepmc.org/abstract/MED/19287371

Phase II trial of Belagenpumatucel-L, a TGF-beta2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients. (English)

1 reference

Europe PubMed Central

11 April 2018

http://europepmc.org/abstract/MED/19287371

phase II clinical trial

0 references

1 reference

based on heuristic

inferred from title

author name string

J Nemunaitis

1

1 reference

Europe PubMed Central

11 April 2018

http://europepmc.org/abstract/MED/19287371

M Nemunaitis

2

1 reference

Europe PubMed Central

11 April 2018

http://europepmc.org/abstract/MED/19287371

N Senzer

3

1 reference

Europe PubMed Central

11 April 2018

http://europepmc.org/abstract/MED/19287371

P Snitz

4

1 reference

Europe PubMed Central

11 April 2018

http://europepmc.org/abstract/MED/19287371

C Bedell

5

1 reference

Europe PubMed Central

11 April 2018

http://europepmc.org/abstract/MED/19287371

P Kumar

6

1 reference

Europe PubMed Central

11 April 2018

http://europepmc.org/abstract/MED/19287371

B Pappen

7

1 reference

Europe PubMed Central

11 April 2018

http://europepmc.org/abstract/MED/19287371

P B Maples

8

1 reference

Europe PubMed Central

11 April 2018

http://europepmc.org/abstract/MED/19287371

D Shawler

9

1 reference

Europe PubMed Central

11 April 2018

http://europepmc.org/abstract/MED/19287371

H Fakhrai

10

1 reference

Europe PubMed Central

11 April 2018

http://europepmc.org/abstract/MED/19287371

publication date

13 March 2009

1 reference

Europe PubMed Central

11 April 2018

http://europepmc.org/abstract/MED/19287371

Cancer Gene Therapy

1 reference

Europe PubMed Central

11 April 2018

http://europepmc.org/abstract/MED/19287371

16

1 reference

Europe PubMed Central

11 April 2018

http://europepmc.org/abstract/MED/19287371

620-624

1 reference

Europe PubMed Central

11 April 2018

http://europepmc.org/abstract/MED/19287371

8

1 reference

Europe PubMed Central

11 April 2018

http://europepmc.org/abstract/MED/19287371

https://scigraph.springernature.com/pub.10.1038/cgt.2009.15

0 references

The TGF-beta family of growth and differentiation factors.

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.15

21 January 2018

Transforming growth factor-beta in disease: the dark side of tissue repair

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.15

21 January 2018

Transforming growth factor-beta inhibits interferon-gamma secretion by lymphokine-activated killer cells stimulated with tumor cells.

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.15

21 January 2018

Factors, including transforming growth factor beta, released in the glioblastoma residual cavity, impair activity of adherent lymphokine-activated killer cells.

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.15

21 January 2018

Circulating tumor cells, disease progression, and survival in metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.15

21 January 2018

Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.15

21 January 2018

The development of immunotherapies for non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.15

21 January 2018

A randomized trial of adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 versus standard therapy in the postoperative treatment of resected nonsmall cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.15

21 January 2018

Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma.

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.15

21 January 2018

Vaccines in cancer: GVAX, a GM-CSF gene vaccine

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.15

21 January 2018

Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.15

21 January 2018

Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.15

21 January 2018

Circulating tumor cells versus imaging--predicting overall survival in metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.15

21 January 2018

Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.15

21 January 2018

Deactivation of macrophages by transforming growth factor-β

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.15

21 January 2018

Transforming growth factor-beta: biological function and chemical structure

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.15

7 January 2021

based on heuristic

inferred from DOI database lookup

Plasma transforming growth factor-beta1 level before radiotherapy correlates with long term outcome of patients with lung carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.15

7 January 2021

based on heuristic

inferred from DOI database lookup

Generation of lymphokine-activated killer cells in human ovarian carcinoma ascitic fluid: identification of transforming growth factor-beta as a suppressive factor

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.15

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.15

7 January 2021

based on heuristic

inferred from DOI database lookup

Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.15

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized study of immunotherapy with low-dose subcutaneous interleukin-2 plus melatonin vs chemotherapy with cisplatin and etoposide as first-line therapy for advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.15

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of combined immunotherapy, chemotherapy, and radiotherapy in the postoperative treatment of advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.15

7 January 2021

based on heuristic

inferred from DOI database lookup

Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.15

7 January 2021

based on heuristic

inferred from DOI database lookup

Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.15

7 January 2021

based on heuristic

inferred from DOI database lookup

Circulating Tumor Cell Number and Prognosis in Progressive Castration-Resistant Prostate Cancer

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.15

7 January 2021

based on heuristic

inferred from DOI database lookup

Quantification and phenotypic characterization of circulating tumor cells for monitoring response to a preventive HER2/neu vaccine-based immunotherapy for breast cancer: a pilot study

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.15

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/CGT.2009.15

1 reference

Europe PubMed Central

11 April 2018

http://europepmc.org/abstract/MED/19287371

1 reference

Europe PubMed Central

11 April 2018

http://europepmc.org/abstract/MED/19287371

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51768350&oldid=1541409343"